missing translation for 'onlineSavingsMsg'
Learn More

Invitrogen™ Canakinumab Recombinant Monoclonal Antibody
GREENER_CHOICE

Recombinant Monoclonal Antibody

£397.00 - £1002.00

Specifications

Antigen Canakinumab
Concentration 1 mg/mL
Content And Storage -20°C, Avoid Freeze/Thaw Cycles
Applications ELISA, Flow Cytometry, Functional Assay, Surface Plasmon Resonance
Classification Recombinant Monoclonal
View More Specs

Products 2
Product Code Brand Quantity Price Quantity & Availability  
Product Code Brand Quantity Price Quantity & Availability  
30283365
GREENER_CHOICE
View Documents
Invitrogen™
MA558961
100 μg
£397.00
100µg
View alternative products
Save Up to 
»
Please to purchase this item. Need a web account? Register with us today!
30283086
View Documents
Invitrogen™
MA558962
1 mg
£1002.00
1mg
View alternative products
Save Up to 
»
Please to purchase this item. Need a web account? Register with us today!
Description

Description

For reconstitution, add sterile, distilled water to achieve a final antibody concentration of 1 mg/mL. Gently shake to solubilize the protein completely. Do not vortex. Reconstituted products should be stored at -80 °.

Canakinumab is a recombinant, human anti-human-IL-1beta monoclonal antibody that belongs to the IgG1/kappa isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. Both heavy chains of canakinumab contain oligosaccharide chains linked to the protein backbone at asparagine 298 (Asn298). Canakinumab binds to human IL-1beta and neutralizes its inflammatory activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1alpha or IL-1 receptor antagonist (IL-1ra). Canakinumab is marketed under the brand name Ilaris and indicated for patients 4 years of age and older to treat Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), which are both part of the Cryopyrin-Associated Periodic Syndromes (CAPS) as well as for patients 2 years of age and older to treat systemic juvenile idiopathic arthritis (SJIA). Clinical trials have established the administration of canakinumab every 2 weeks to be safe and effective, offering a considerable advantage over the existing treatment with the human IL-1 receptor antagonist, anakinra, which must be injected daily and which is often poorly tolerated by patients.
Specifications

Specifications

Canakinumab
-20°C, Avoid Freeze/Thaw Cycles
Recombinant Monoclonal
Lyophilized
IgG1 κ
Human
ACZ885
Antibody
1 mg/mL
ELISA, Flow Cytometry, Functional Assay, Surface Plasmon Resonance
Unconjugated
Human
RUO
25mM histidine with 8% sucrose, 0.01% Tween 80 and no preservative; pH 6.2
Primary
Protein A
Videos
SDS
Documents

Documents

Product Certifications
Product Content Correction

Your input is important to us. Please complete this form to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Thank You! Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.